TY - JOUR
T1 - Circulating tumour DNA and melanoma survival
T2 - a systematic literature review and meta-analysis
AU - Gandini, Sara
AU - Zanna, Ines
AU - De Angelis, Simone Pietro
AU - Cocorocchio, Emilia
AU - Queirolo, Paola
AU - Lee, Jenny H.
AU - Carlino, Matteo S.
AU - Mazzarella, Luca
AU - Achutti Duso, Bruno
AU - Palli, Domenico
AU - Raimondi, Sara
AU - Caini, Saverio
PY - 2021/1
Y1 - 2021/1
N2 - We reviewed and meta-analysed the available evidence (until December 2019) about circulating tumour DNA (ctDNA) levels and melanoma patients survival. We included twenty-six studies (>2000 patients overall), which included mostly stage III-IV cutaneous melanoma patients and differed widely in terms of systemic therapy received and somatic mutations that were searched. Patients with detectable ctDNA before treatment had worse progression-free survival (PFS) (summary hazard ratio (SHR) 2.47, 95 % confidence intervals (CI) 1.85–3.29) and overall survival (OS) (SHR 2.98, 95 % CI 2.26–3.92), with no difference by tumour stage. ctDNA detectability during follow-up was associated with poorer PFS (SHR 4.27, 95 %CI 2.75–6.63) and OS (SHR 3.91, 95 %CI 1.97–7.78); in the latter case, the association was stronger (p = 0.01) for stage IV vs. III melanomas. Between-estimates heterogeneity was low for all pooled estimates. ctDNA is a strong prognostic biomarker for advanced-stage melanoma patients, robust across tumour (e.g. genomic profile) and patients (e.g. systemic therapy) characteristics.
AB - We reviewed and meta-analysed the available evidence (until December 2019) about circulating tumour DNA (ctDNA) levels and melanoma patients survival. We included twenty-six studies (>2000 patients overall), which included mostly stage III-IV cutaneous melanoma patients and differed widely in terms of systemic therapy received and somatic mutations that were searched. Patients with detectable ctDNA before treatment had worse progression-free survival (PFS) (summary hazard ratio (SHR) 2.47, 95 % confidence intervals (CI) 1.85–3.29) and overall survival (OS) (SHR 2.98, 95 % CI 2.26–3.92), with no difference by tumour stage. ctDNA detectability during follow-up was associated with poorer PFS (SHR 4.27, 95 %CI 2.75–6.63) and OS (SHR 3.91, 95 %CI 1.97–7.78); in the latter case, the association was stronger (p = 0.01) for stage IV vs. III melanomas. Between-estimates heterogeneity was low for all pooled estimates. ctDNA is a strong prognostic biomarker for advanced-stage melanoma patients, robust across tumour (e.g. genomic profile) and patients (e.g. systemic therapy) characteristics.
KW - Circulating tumour DNA
KW - Melanoma
KW - Meta-analysis
KW - Review
KW - Survival
UR - http://www.scopus.com/inward/record.url?scp=85096960196&partnerID=8YFLogxK
U2 - 10.1016/j.critrevonc.2020.103187
DO - 10.1016/j.critrevonc.2020.103187
M3 - Review article
C2 - 33276181
AN - SCOPUS:85096960196
SN - 1040-8428
VL - 157
SP - 1
EP - 8
JO - Critical Reviews in Oncology/Hematology
JF - Critical Reviews in Oncology/Hematology
M1 - 103187
ER -